Memorial Hospital of Rhode Island
The Cancer Center
Clinical Trials
(See key at end of page for descriptions of study sponsors)
Phases of Clinical TrialsMost clinical research that involves the testing of a new drug progresses in an orderly series of steps, called phases. This allows researchers to ask and answer questions in a way that results in reliable information about the drug and protects the patients. Most clinical trials are classified into one of three phases:
- Phase I trials: These first studies in people evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle), how often, and what dose is safe. A phase I trial usually enrolls only a small number of patients, sometimes as few as a dozen.
- Phase II trials: A phase II trial continues to test the safety of the drug, and begins to evaluate how well the new drug works. Phase II studies usually focus on a particular type of cancer.
- Phase III trials: These studies test a new drug, a new combination of drugs, or a new surgical procedure in comparison to the current standard. A participant will usually be assigned to the standard group or the new group at random (called randomization). Phase III trials often enroll large numbers of people and may be conducted at many doctors' offices, clinics, and cancer centers nationwide
- In addition, after a treatment has been approved and is being marketed, the drug's maker may study it further in a phase IV trial. The purpose of phase IV trials is to evaluate the side effects, risks, and benefits of a drug over a longer period of time and in a larger number of people than in phase III clinical trials. Thousands of people are involved in a phase IV trial.
LUNG CANCERTitle: Adjuvant chemotherapy with or without Avastin for resected Stage IB-IIIA NSCLC
Phase: III
Modality: Chemotherapy and biological
Sponsor: CTSU
Title: Sunitinib or Placebo following 4 cycles of platinum based chemotherapy in Stage IIIB-IV NSCLC
Phase: III
Modality: Chemotherapy/Immunotherapy
Sponsor: CALGB
Title: Stereotactic Body Radiation Therapy for consolidation after Chemotherapy/Radiation Therapy in stage III Lung Cancer
Phase: II
Modality: Radiation Therapy
Sponsor: BrUOG
Title: Progression of Metastatic Non-Small Cell Lung Cancer on Maintenance Avastin- Continue Avastin or Not?
Phase: III
Modality: Biologic
Sponsor: Genentech
GASTROINTESTINAL/HEPATIC CANCER
Title: 6 or 12 cycles of adjuvant Folfox plus either Celecoxib or placebo for resected Stage III (note +) Colon Cancer
Phase: III
Modality: Chemotherapy
Sponsor: CALGB
Title: Eribulin Mesylate and Cetuximab for Advanced Colo-Rectal Cancer: > 2 Lines of therapy, wild type positive
Phase: I
Modality: Chemotherapy
Sponsor: BrUOG
Title: Docetaxel/Prednisone vs Cabazitaxel/Prednisone 20mg or 25mg q 3 weeks for first line Metastatic Prostate Cancer
Phase: III
Modality: Chemotherapy
Sponsor: S/A EFC
Title: FOLFOX-A for Metastatic/Advanced Pancreatic Cancer
Phase: III
Modality: Chemotherapy
Sponsor: BrUOG
LEUKEMIA/LYMPHOMA
Title: Ofatumumab or Velcade following Rituximab for Low grade NHL Relapse
Phase: III
Modality: Immunotherapy
Sponsor: BrUOG
Title: Lab Study for AML/ALL/MDS/CML: Genetic Alterations in Hematopoietic Cells using blood and bone marrow cells
Phase: NA
Modality: Lab Study
Sponsor: RWMC
HEAD AND NECK CANCER
Title: Eribulin Mesylate and Cetuximab for Advanced Head and Neck Cancer following one prior therapy
Phase: I
Modality: Chemotherapy
Sponsor: BrUOG
OTHER
Title: Adjuvant Ipilimumab vs Interferon for resected High-Risk Melanoma
Phase: III
Modality: Immunotherapy, Biological
Sponsor: CTSU
Title: Assessment of the effectiveness of Chemotherapy teaching
Phase: NA
Modality: Observational
Sponsor: BrUOG
Description of study sponsors:
* BrUOG = Brown University Oncology Group
* CALGB = Cancer and Leukemia Group B
* CTSU = Clinical Trials Support Unit
* IBCSG = International Breast Cancer Study Group
* MHRI = Memorial Hospital of Rhode Island
* NSABP = National Surgical Adjuvant Breast and Bowel Project
* RTOG = Radiation Therapy Oncology Group
* SWOG = Southwest Oncology Group
(Revised 3/5/13)